Pharmacological and molecular approaches for the treatment of β-hemoglobin disorders.

about

Pharmacological and molecular approaches for the treatment of β-hemoglobin disorders.

Item

http://www.wikidata.org/entity/Q45874809

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Pharmacological and molecular approaches for the treatment of β-hemoglobin disorders.

@en

Pharmacological and molecular approaches for the treatment of β-hemoglobin disorders.

@nl

type

Item

label

Pharmacological and molecular approaches for the treatment of β-hemoglobin disorders.

@en

Pharmacological and molecular approaches for the treatment of β-hemoglobin disorders.

@nl

prefLabel

Pharmacological and molecular approaches for the treatment of β-hemoglobin disorders.

@en

Pharmacological and molecular approaches for the treatment of β-hemoglobin disorders.

@nl

P1476

Pharmacological and molecular approaches for the treatment of β-hemoglobin disorders

@en

P2093

Anjana Munshi

http://www.w3.org/2001/XMLSchema#string

Neelam Lohani

http://www.w3.org/2001/XMLSchema#string

Nupur Bhargava

http://www.w3.org/2001/XMLSchema#string

P2860

Beta-thalassemia

Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin

A dominant mutation in the gene encoding the erythroid transcription factor KLF1 causes a congenital dyserythropoietic anemia

An embryonic/fetal beta-type globin gene repressor contains a nuclear receptor TR2/TR4 heterodimer

Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain

DNA-binding specificities of the GATA transcription factor family

Targeting DNA double-strand breaks with TAL effector nucleases

Multiplex genome engineering using CRISPR/Cas systems

Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor

Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia

P304

4563-4577

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JCP.26292

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

233

http://www.w3.org/2001/XMLSchema#string

P50

Sivaprakash Ramalingam

P577

2017-12-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29159826

http://www.w3.org/2001/XMLSchema#string